secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001193125-25-277580
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Enliven Q3 net loss $20.1M; cash $477.6M; Phase 1b enrollment completed for ELVN-001
--------------------------------------------------------------------------------

- Net loss $20.1M in Q3 2025 vs $23.2M in Q3 2024; R&D expenses $18.2M vs $21.3M.
- Cash, cash equivalents and marketable securities $477.6M; runway into first half 2029.
- Completed randomized Phase 1b portion of ENABLE trial evaluating ELVN-001 in CML patients.
- On track to initiate Phase 3 pivotal trial for ELVN-001 in 2026.
- Data from ELVN-001 in CML patients with atypical fusion transcripts to be presented at ASH 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525277580/0001193125-25-277580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312525277580/elvn-20251112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-277580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer